Search Results for: NCM-MCI-6.5 Tests 🍟 NCM-MCI-6.5 Online Test 🍰 NCM-MCI-6.5 Demotesten 📔 Suchen Sie jetzt auf ▶ www.itzert.com ◀ nach ▛ NCM-MCI-6.5 ▟ und laden Sie es kostenlos herunter 😭NCM-MCI-6.5 Zertifizierungsfragen
Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: Are we evaluating the orally administered cephalosporins correctly?
Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: Are we evaluating the orally administered cephalosporins correctly? by Jones…
Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): Emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
…resistant organism populations and generally untested species causing community-acquired respiratory tract infections. by Johnson DM, Biedenbach D and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (1): 49-60…
Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group.
Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group. by Doern GV, Jones RN, Pfaller MA,…
CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.
CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. by Pfaller MA, Messer SA, Rhomberg…
In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.
In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018. by Messer SA, Carvalhaes CG, Castanheira M and Pfaller MA published in Diagn….
Antimicrobial activities of ceftaroline and comparator agents against bacterial organisms causing bacteremia in patients with skin and skin structure infections in U.S. Medical Centers, 2008 to 2014.
Antimicrobial activities of ceftaroline and comparator agents against bacterial organisms causing bacteremia in patients with skin and skin structure infections in U.S. Medical Centers, 2008 to 2014. by Sader HS,…
Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY antimicrobial surveillance program.
Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY antimicrobial surveillance program. by Farrell DJ, Liverman LC, Biedenbach DJ, Flamm RK…
Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis.
Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. by Gales AC, Sader HS, Andrade SS, Lutz L, Machado A and Barth AL…
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY Antimicrobial Surveillance Program.
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. by Doern GV, Pfaller MA, Kugler K, Freeman…
Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients.
Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients. by Sader HS, Duncan LR, Doyle TB and Castanheira M. published in JAC Antimicrob. Resist….
